Mevacor Daily Regimen Compliance Questioned By FDA Committees
This article was originally published in The Tan Sheet
Executive Summary
A joint FDA advisory committee review of J&J/Merck's nonprescription Mevacor Daily centered in part on long-term consumer compliance with the indicated cholesterol-lowering regimen
You may also be interested in...
Merck’s Mevacor Returns For OTC Switch Consideration
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug
Merck’s Mevacor Returns For OTC Switch Consideration
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug
Merck’s Mevacor Returns For OTC Switch Consideration
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug